Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

Anti-miR-21 Suppresses Hepatocellular Carcinoma Growth via Broad Transcriptional Network Deregulation.

Wagenaar TR, Zabludoff S, Ahn SM, Allerson C, Arlt H, Baffa R, Cao H, Davis S, Garcia-Echeverria C, Gaur R, Huang SM, Jiang L, Kim D, Metz-Weidmann C, Pavlicek A, Pollard J, Reeves J, Rocnik JL, Scheidler S, Shi C, Sun F, Tolstykh T, Weber W, Winter C, Yu E, Yu Q, Zheng G, Wiederschain D.

Mol Cancer Res. 2015 Jun;13(6):1009-21. doi: 10.1158/1541-7786.MCR-14-0703. Epub 2015 Mar 10.

2.

MicroRNAs as tools and effectors for patient treatment in gastrointestinal carcinogenesis.

D'Angelo E, Vicentini C, Agostini M, Kiss A, Baffa R, Scarpa A, Fassan M.

Curr Drug Targets. 2015;16(4):383-92. Review.

PMID:
25495924
3.

Pluripotent stem cell miRNAs and metastasis in invasive breast cancer.

Volinia S, Nuovo G, Drusco A, Costinean S, Abujarour R, Desponts C, Garofalo M, Baffa R, Aeqilan R, Maharry K, Sana ME, Di Leva G, Gasparini P, Dama P, Marchesini J, Galasso M, Manfrini M, Zerbinati C, Corrà F, Wise T, Wojcik SE, Previati M, Pichiorri F, Zanesi N, Alder H, Palatini J, Huebner KF, Shapiro CL, Negrini M, Vecchione A, Rosenberg AL, Croce CM, Garzon R.

J Natl Cancer Inst. 2014 Oct 11;106(12). pii: dju324. doi: 10.1093/jnci/dju324. Print 2014 Dec. Erratum in: J Natl Cancer Inst. 2014 Nov:106(11):dju373doi:10.1093/jnci/dju373. Garzon, Maria Elena Sana Ramiro [Corrected to Garzon, Ramiro and Sana, Maria Elena].

4.

Transcribed ultraconserved noncoding RNAs (T-UCR) are involved in Barrett's esophagus carcinogenesis.

Fassan M, Dall'Olmo L, Galasso M, Braconi C, Pizzi M, Realdon S, Volinia S, Valeri N, Gasparini P, Baffa R, Souza RF, Vicentini C, D'Angelo E, Bornschein J, Nuovo GJ, Zaninotto G, Croce CM, Rugge M.

Oncotarget. 2014 Aug 30;5(16):7162-71.

5.

Decorin induces mitophagy in breast carcinoma cells via peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α) and mitostatin.

Neill T, Torres A, Buraschi S, Owens RT, Hoek JB, Baffa R, Iozzo RV.

J Biol Chem. 2014 Feb 21;289(8):4952-68. doi: 10.1074/jbc.M113.512566. Epub 2014 Jan 8.

6.

Advanced precancerous lesions within the GI tract: the molecular background.

Fassan M, Baffa R, Kiss A.

Best Pract Res Clin Gastroenterol. 2013 Apr;27(2):159-69. doi: 10.1016/j.bpg.2013.03.009. Review.

PMID:
23809238
7.

MicroRNAs and targeted therapy: small molecules of unlimited potentials.

Fassan M, Baffa R.

Curr Opin Genet Dev. 2013 Feb;23(1):75-7. doi: 10.1016/j.gde.2013.02.009. Epub 2013 Mar 22. No abstract available.

PMID:
23523049
8.

MicroRNA dysregulation in esophageal neoplasia: the biological rationale for novel therapeutic options.

Fassan M, Baffa R, Kiss A, Zaninotto G, Rugge M.

Curr Pharm Des. 2013;19(7):1236-41. Review.

PMID:
23092347
9.

Role of miRNA in distinguishing primary brain tumors from secondary tumors metastatic to the brain.

Fassan M, Sachsenmeir K, Rugge M, Baffa R.

Front Biosci (Schol Ed). 2011 Jun 1;3:970-9. Review.

PMID:
21622246
10.

Mitostatin is down-regulated in human prostate cancer and suppresses the invasive phenotype of prostate cancer cells.

Fassan M, D'Arca D, Letko J, Vecchione A, Gardiman MP, McCue P, Wildemore B, Rugge M, Shupp-Byrne D, Gomella LG, Morrione A, Iozzo RV, Baffa R.

PLoS One. 2011 May 6;6(5):e19771. doi: 10.1371/journal.pone.0019771.

11.

MicroRNA expression profiling in human Barrett's carcinogenesis.

Fassan M, Volinia S, Palatini J, Pizzi M, Baffa R, De Bernard M, Battaglia G, Parente P, Croce CM, Zaninotto G, Ancona E, Rugge M.

Int J Cancer. 2011 Oct 1;129(7):1661-70. doi: 10.1002/ijc.25823. Epub 2011 Mar 11.

12.

Trichoplein/mitostatin regulates endoplasmic reticulum-mitochondria juxtaposition.

Cerqua C, Anesti V, Pyakurel A, Liu D, Naon D, Wiche G, Baffa R, Dimmer KS, Scorrano L.

EMBO Rep. 2010 Nov;11(11):854-60. doi: 10.1038/embor.2010.151. Epub 2010 Oct 8.

13.

Reprogramming of miRNA networks in cancer and leukemia.

Volinia S, Galasso M, Costinean S, Tagliavini L, Gamberoni G, Drusco A, Marchesini J, Mascellani N, Sana ME, Abu Jarour R, Desponts C, Teitell M, Baffa R, Aqeilan R, Iorio MV, Taccioli C, Garzon R, Di Leva G, Fabbri M, Catozzi M, Previati M, Ambs S, Palumbo T, Garofalo M, Veronese A, Bottoni A, Gasparini P, Harris CC, Visone R, Pekarsky Y, de la Chapelle A, Bloomston M, Dillhoff M, Rassenti LZ, Kipps TJ, Huebner K, Pichiorri F, Lenze D, Cairo S, Buendia MA, Pineau P, Dejean A, Zanesi N, Rossi S, Calin GA, Liu CG, Palatini J, Negrini M, Vecchione A, Rosenberg A, Croce CM.

Genome Res. 2010 May;20(5):589-99. doi: 10.1101/gr.098046.109.

14.

The insulin-like growth factor receptor I promotes motility and invasion of bladder cancer cells through Akt- and mitogen-activated protein kinase-dependent activation of paxillin.

Metalli D, Lovat F, Tripodi F, Genua M, Xu SQ, Spinelli M, Alberghina L, Vanoni M, Baffa R, Gomella LG, Iozzo RV, Morrione A.

Am J Pathol. 2010 Jun;176(6):2997-3006. doi: 10.2353/ajpath.2010.090904. Epub 2010 Apr 15.

15.

Genetic inactivation of ApoJ/clusterin: effects on prostate tumourigenesis and metastatic spread.

Bettuzzi S, Davalli P, Davoli S, Chayka O, Rizzi F, Belloni L, Pellacani D, Fregni G, Astancolle S, Fassan M, Corti A, Baffa R, Sala A.

Oncogene. 2009 Dec 10;28(49):4344-52. doi: 10.1038/onc.2009.286.

PMID:
19784068
16.

Cyclin D1 splice variants: polymorphism, risk, and isoform-specific regulation in prostate cancer.

Comstock CE, Augello MA, Benito RP, Karch J, Tran TH, Utama FE, Tindall EA, Wang Y, Burd CJ, Groh EM, Hoang HN, Giles GG, Severi G, Hayes VM, Henderson BE, Le Marchand L, Kolonel LN, Haiman CA, Baffa R, Gomella LG, Knudsen ES, Rui H, Henshall SM, Sutherland RL, Knudsen KE.

Clin Cancer Res. 2009 Sep 1;15(17):5338-49. doi: 10.1158/1078-0432.CCR-08-2865. Epub 2009 Aug 25.

17.

MicroRNA expression profiling of male breast cancer.

Fassan M, Baffa R, Palazzo JP, Lloyd J, Crosariol M, Liu CG, Volinia S, Alder H, Rugge M, Croce CM, Rosenberg A.

Breast Cancer Res. 2009;11(4):R58. doi: 10.1186/bcr2348. Epub 2009 Aug 10.

18.

MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets.

Baffa R, Fassan M, Volinia S, O'Hara B, Liu CG, Palazzo JP, Gardiman M, Rugge M, Gomella LG, Croce CM, Rosenberg A.

J Pathol. 2009 Oct;219(2):214-21. doi: 10.1002/path.2586.

PMID:
19593777
19.

BaS analysis: suggesting a new cephalometric model in follow-up of patients with craniostenosis who underwent craniofacial advancement surgery after 1 year from the end of the distraction protocol.

Gasparini G, Cacucci L, Di Nardo F, Moro A, Boniello R, Baffa R, Deli R, Pelo S.

J Craniofac Surg. 2009 May;20(3):895-8. doi: 10.1097/SCS.0b013e3181a2ef62.

PMID:
19381100
20.

Prevention of urinary bladder cancer in the FHIT knock-out mouse with Rofecoxib, a Cox-2 inhibitor.

D'Arca D, LeNoir J, Wildemore B, Gottardo F, Bragantini E, Shupp-Byrne D, Zanesi N, Fassan M, Croce CM, Gomella LG, Baffa R.

Urol Oncol. 2010 Mar-Apr;28(2):189-94. doi: 10.1016/j.urolonc.2009.01.016. Epub 2009 Apr 16.

PMID:
19372053
21.

Proepithelin is an autocrine growth factor for bladder cancer.

Lovat F, Bitto A, Xu SQ, Fassan M, Goldoni S, Metalli D, Wubah V, McCue P, Serrero G, Gomella LG, Baffa R, Iozzo RV, Morrione A.

Carcinogenesis. 2009 May;30(5):861-8. doi: 10.1093/carcin/bgp050. Epub 2009 Feb 23.

22.

Proepithelin regulates prostate cancer cell biology by promoting cell growth, migration, and anchorage-independent growth.

Monami G, Emiliozzi V, Bitto A, Lovat F, Xu SQ, Goldoni S, Fassan M, Serrero G, Gomella LG, Baffa R, Iozzo RV, Morrione A.

Am J Pathol. 2009 Mar;174(3):1037-47. doi: 10.2353/ajpath.2009.080735. Epub 2009 Jan 29.

23.

MITOSTATIN, a putative tumor suppressor on chromosome 12q24.1, is downregulated in human bladder and breast cancer.

Vecchione A, Fassan M, Anesti V, Morrione A, Goldoni S, Baldassarre G, Byrne D, D'Arca D, Palazzo JP, Lloyd J, Scorrano L, Gomella LG, Iozzo RV, Baffa R.

Oncogene. 2009 Jan 15;28(2):257-69. doi: 10.1038/onc.2008.381. Epub 2008 Oct 20.

24.

An antimetastatic role for decorin in breast cancer.

Goldoni S, Seidler DG, Heath J, Fassan M, Baffa R, Thakur ML, Owens RT, McQuillan DJ, Iozzo RV.

Am J Pathol. 2008 Sep;173(3):844-55. doi: 10.2353/ajpath.2008.080275. Epub 2008 Aug 7.

25.

Fez1/Lzts1-deficient mice are more susceptible to N-butyl-N-(4-hydroxybutil) nitrosamine (BBN) carcinogenesis.

Baffa R, Fassan M, Sevignani C, Vecchione A, Ishii H, Giarnieri E, Iozzo RV, Gomella LG, Croce CM.

Carcinogenesis. 2008 Apr;29(4):846-8. doi: 10.1093/carcin/bgn006. Epub 2008 Jan 12.

PMID:
18192690
26.

Targeted therapies in the management of metastatic bladder cancer.

Fassan M, Trabulsi EJ, Gomella LG, Baffa R.

Biologics. 2007 Dec;1(4):393-406.

27.

Micro-RNA profiling in kidney and bladder cancers.

Gottardo F, Liu CG, Ferracin M, Calin GA, Fassan M, Bassi P, Sevignani C, Byrne D, Negrini M, Pagano F, Gomella LG, Croce CM, Baffa R.

Urol Oncol. 2007 Sep-Oct;25(5):387-92.

PMID:
17826655
28.

Molecular genetics of prostate cancer: clinical translational opportunities.

Vecchione A, Gottardo F, Gomella LG, Wildemore B, Fassan Ms, Bragantini E, Pagano F, Baffa R.

J Exp Clin Cancer Res. 2007 Mar;26(1):25-37. Review.

PMID:
17550130
29.

Fez1/Lzts1 absence impairs Cdk1/Cdc25C interaction during mitosis and predisposes mice to cancer development.

Vecchione A, Baldassarre G, Ishii H, Nicoloso MS, Belletti B, Petrocca F, Zanesi N, Fong LY, Battista S, Guarnieri D, Baffa R, Alder H, Farber JL, Donovan PJ, Croce CM.

Cancer Cell. 2007 Mar;11(3):275-89.

30.

Chromosomal deletions in bladder cancer: shutting down pathways.

Abraham R, Pagano F, Gomella LG, Baffa R.

Front Biosci. 2007 Jan 1;12:826-38. Review.

PMID:
17127340
31.

Molecular genetics of bladder cancer: targets for diagnosis and therapy.

Baffa R, Letko J, McClung C, LeNoir J, Vecchione A, Gomella LG.

J Exp Clin Cancer Res. 2006 Jun;25(2):145-60. Review.

PMID:
16918124
32.

Proepithelin promotes migration and invasion of 5637 bladder cancer cells through the activation of ERK1/2 and the formation of a paxillin/FAK/ERK complex.

Monami G, Gonzalez EM, Hellman M, Gomella LG, Baffa R, Iozzo RV, Morrione A.

Cancer Res. 2006 Jul 15;66(14):7103-10.

33.

Loss of Fhit expression is associated with poorer survival in gastric cancer but is not an independent prognostic marker.

Bragantini E, Barbi S, Beghelli S, Moore PS, de Manzoni G, Roviello F, Tomezzoli A, Vindigni C, Baffa R, Scarpa A.

J Cancer Res Clin Oncol. 2006 Jan;132(1):45-50. Epub 2005 Oct 11.

PMID:
16217683
34.

Familial cancer associated with a polymorphism in ARLTS1.

Calin GA, Trapasso F, Shimizu M, Dumitru CD, Yendamuri S, Godwin AK, Ferracin M, Bernardi G, Chatterjee D, Baldassarre G, Rattan S, Alder H, Mabuchi H, Shiraishi T, Hansen LL, Overgaard J, Herlea V, Mauro FR, Dighiero G, Movsas B, Rassenti L, Kipps T, Baffa R, Fusco A, Mori M, Russo G, Liu CG, Neuberg D, Bullrich F, Negrini M, Croce CM.

N Engl J Med. 2005 Apr 21;352(16):1667-76.

35.

Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer.

Iliopoulos D, Guler G, Han SY, Johnston D, Druck T, McCorkell KA, Palazzo J, McCue PA, Baffa R, Huebner K.

Oncogene. 2005 Feb 24;24(9):1625-33.

PMID:
15674328
36.

Inactivation of the FHIT gene favors bladder cancer development.

Vecchione A, Sevignani C, Giarnieri E, Zanesi N, Ishii H, Cesari R, Fong LY, Gomella LG, Croce CM, Baffa R.

Clin Cancer Res. 2004 Nov 15;10(22):7607-12.

37.

Collecting duct carcinoma of the kidney: an immunohistochemical study of 11 cases.

Vecchione A, Galetti TP, Gardiman M, Ishii H, Giarnieri E, Pagano F, Gomella LG, Croce CM, Baffa R.

BMC Urol. 2004 Sep 9;4:11.

38.

Loss of WWOX expression in gastric carcinoma.

Aqeilan RI, Kuroki T, Pekarsky Y, Albagha O, Trapasso F, Baffa R, Huebner K, Edmonds P, Croce CM.

Clin Cancer Res. 2004 May 1;10(9):3053-8.

39.

Cancer prevention and therapy in a preclinical mouse model: impact of FHIT viruses.

Ishii H, Vecchione A, Fong LY, Zanesi N, Trapasso F, Furukawa Y, Baffa R, Huebner K, Croce CM.

Curr Gene Ther. 2004 Mar;4(1):53-63. Review.

PMID:
15032614
40.

Regression of upper gastric cancer in mice by FHIT gene delivery.

Ishii H, Zanesi N, Vecchione A, Trapasso F, Yendamuri S, Sarti M, Baffa R, During MJ, Huebner K, Fong LY, Croce CM.

FASEB J. 2003 Sep;17(12):1768-70. Epub 2003 Jul 3.

PMID:
12958204
41.

A novel interaction between perlecan protein core and progranulin: potential effects on tumor growth.

Gonzalez EM, Mongiat M, Slater SJ, Baffa R, Iozzo RV.

J Biol Chem. 2003 Oct 3;278(40):38113-6. Epub 2003 Aug 4.

42.

Intracellular redistribution of nuclear and nucleolar proteins during differentiation of 32D murine hemopoietic cells.

Tu X, Baffa R, Luke S, Prisco M, Baserga R.

Exp Cell Res. 2003 Aug 1;288(1):119-30.

PMID:
12878164
43.

Expression and transcriptional regulation of caspase-14 in simple and complex epithelia.

Pistritto G, Jost M, Srinivasula SM, Baffa R, Poyet JL, Kari C, Lazebnik Y, Rodeck U, Alnemri ES.

Cell Death Differ. 2002 Sep;9(9):995-1006.

44.

Nuclear translocation of insulin receptor substrate-1 by the simian virus 40 T antigen and the activated type 1 insulin-like growth factor receptor.

Prisco M, Santini F, Baffa R, Liu M, Drakas R, Wu A, Baserga R.

J Biol Chem. 2002 Aug 30;277(35):32078-85. Epub 2002 Jun 12.

45.

FEZ1/LZTS1 is down-regulated in high-grade bladder cancer, and its restoration suppresses tumorigenicity in transitional cell carcinoma cells.

Vecchione A, Ishii H, Baldassarre G, Bassi P, Trapasso F, Alder H, Pagano F, Gomella LG, Croce CM, Baffa R.

Am J Pathol. 2002 Apr;160(4):1345-52.

46.

Potential cancer therapy with the fragile histidine triad gene: review of the preclinical studies.

Ishii H, Dumon KR, Vecchione A, Fong LY, Baffa R, Huebner K, Croce CM.

JAMA. 2001 Nov 21;286(19):2441-9. Review.

PMID:
11712940
47.

FEZ1/LZTS1 gene at 8p22 suppresses cancer cell growth and regulates mitosis.

Ishii H, Vecchione A, Murakumo Y, Baldassarre G, Numata S, Trapasso F, Alder H, Baffa R, Croce CM.

Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10374-9. Epub 2001 Aug 14.

48.

Fez1/lzts1 alterations in gastric carcinoma.

Vecchione A, Ishii H, Shiao YH, Trapasso F, Rugge M, Tamburrino JF, Murakumo Y, Alder H, Croce CM, Baffa R.

Clin Cancer Res. 2001 Jun;7(6):1546-52.

49.

Fragile histidine triad expression delays tumor development and induces apoptosis in human pancreatic cancer.

Dumon KR, Ishii H, Vecchione A, Trapasso F, Baldassarre G, Chakrani F, Druck T, Rosato EF, Williams NN, Baffa R, During MJ, Huebner K, Croce CM.

Cancer Res. 2001 Jun 15;61(12):4827-36.

50.

FHIT gene therapy prevents tumor development in Fhit-deficient mice.

Dumon KR, Ishii H, Fong LY, Zanesi N, Fidanza V, Mancini R, Vecchione A, Baffa R, Trapasso F, During MJ, Huebner K, Croce CM.

Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3346-51. Epub 2001 Feb 27.

Supplemental Content

Support Center